Literature DB >> 22378628

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.

Suman Malempati1, Douglas S Hawkins.   

Abstract

The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved with refinements in multi-modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma Study Group (now the Children's Oncology Group Soft-Tissue Sarcoma Committee) has conducted serial studies for RMS. This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Year:  2012        PMID： 22378628      PMCID： PMC4008325          DOI： 10.1002/pbc.24118

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  55 in total

Review 1.  Temsirolimus, an inhibitor of mammalian target of rapamycin.

Authors:  Brian I Rini
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

2.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.

Authors:  Jane L Meza; James Anderson; Alberto S Pappo; William H Meyer
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

3.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

Authors:  Alberto S Pappo; Elizabeth Lyden; Phillip Breitfeld; Sarah S Donaldson; Eugene Wiener; David Parham; Kristine R Crews; Peter Houghton; William H Meyer
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

4.  Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Megan Burke; James R Anderson; Simon C Kao; David Rodeberg; Stephen J Qualman; Suzanne L Wolden; William H Meyer; Philip P Breitfeld
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

5.  Cancer incidence among children and adolescents in the United States, 2001-2003.

Authors:  Jun Li; Trevor D Thompson; Jacqueline W Miller; Lori A Pollack; Sherri L Stewart
Journal:  Pediatrics       Date:  2008-06       Impact factor: 7.124

6.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

Authors:  Odile Oberlin; Annie Rey; Elizabeth Lyden; Gianni Bisogno; Michael C G Stevens; William H Meyer; Modesto Carli; James R Anderson
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

7.  Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma.

Authors:  Ling Cen; Kristy J Arnoczky; Fu-Chuan Hsieh; Huey-Jen Lin; Stephen J Qualman; Songlin Yu; Huiyun Xiang; Jiayuh Lin
Journal:  Mod Pathol       Date:  2007-06-22       Impact factor: 7.842

8.  Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Authors:  Lars M Wagner; John P Perentesis; Joel M Reid; Matthew M Ames; Stephanie L Safgren; Marvin D Nelson; Ashish M Ingle; Susan M Blaney; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

9.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

10.  Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  David M Parham; Stephen J Qualman; Lisa Teot; Frederic G Barr; Raphaella Morotti; Poul H B Sorensen; Timothy J Triche; William H Meyer
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394
View more
  129 in total

1.  A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Authors:  Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

Review 2.  Insights into pediatric rhabdomyosarcoma research: Challenges and goals.

Authors:  Marielle E Yohe; Christine M Heske; Elizabeth Stewart; Peter C Adamson; Nabil Ahmed; Cristina R Antonescu; Eleanor Chen; Natalie Collins; Alan Ehrlich; Rene L Galindo; Berkley E Gryder; Heidi Hahn; Sharon Hammond; Mark E Hatley; Douglas S Hawkins; Madeline N Hayes; Andrea Hayes-Jordan; Lee J Helman; Simone Hettmer; Myron S Ignatius; Charles Keller; Javed Khan; David G Kirsch; Corinne M Linardic; Philip J Lupo; Rossella Rota; Jack F Shern; Janet Shipley; Sivasish Sindiri; Stephen J Tapscott; Christopher R Vakoc; Leonard H Wexler; David M Langenau
Journal:  Pediatr Blood Cancer       Date:  2019-06-21       Impact factor: 3.167

3.  Orbital rhabdomyosarcomas: A review.

Authors:  Lama Jurdy; Johanus H M Merks; Bradly R Pieters; Maarten P Mourits; Roel J H M Kloos; Simone D Strackee; Peerooz Saeed
Journal:  Saudi J Ophthalmol       Date:  2013-07

4.  Impact of Surgical Margin in Skull Base Surgery for Head and Neck Sarcomas.

Authors:  Kenya Kobayashi; Fumihiko Matsumoto; Yasuji Miyakita; Taisuke Mori; Tatsunori Shimoi; Naoya Murakami; Akihiko Yoshida; Ayumu Arakawa; Go Omura; Masahiko Fukasawa; Yoshifumi Matsumoto; Satoko Matsumura; Jun Itami; Yoshitaka Narita; Seiichi Yoshimoto
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-09

Review 5.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

6.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

Review 7.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Suman Malempati; Brenda J Weigel; Yueh-Yun Chi; Jing Tian; James R Anderson; David M Parham; Lisa A Teot; David A Rodeberg; Torunn I Yock; Barry L Shulkin; Sheri L Spunt; William H Meyer; Douglas S Hawkins
Journal:  Cancer       Date:  2018-10-23       Impact factor: 6.860

9.  A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Authors:  Adele P Williams; Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2018-03-26       Impact factor: 2.192

10.  The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.

Authors:  Narendra Bharathy; Noah E Berlow; Eric Wang; Jinu Abraham; Teagan P Settelmeyer; Jody E Hooper; Matthew N Svalina; Yoshihiro Ishikawa; Keith Zientek; Zia Bajwa; Martin W Goros; Brian S Hernandez; Johannes E Wolff; Michelle A Rudek; Linping Xu; Nicole M Anders; Ranadip Pal; Alexandria P Harrold; Angela M Davies; Arya Ashok; Darnell Bushby; Maria Mancini; Christopher Noakes; Neal C Goodwin; Peter Ordentlich; James Keck; Douglas S Hawkins; Erin R Rudzinski; Bishwanath Chatterjee; Hans Peter Bächinger; Frederic G Barr; Jennifer Liddle; Benjamin A Garcia; Atiya Mansoor; Theodore J Perkins; Christopher R Vakoc; Joel E Michalek; Charles Keller
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.